Marker Therapeutics (MRKR) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed Psyence Biomedical (PBM) over the past year, losing 7.5% versus a loss of 96.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRKR | PBM |
|---|---|---|
| Share price | $0.9716 | $4.97 |
| Market cap | $16.20M | — |
| 1-day change | +2.27% | -2.93% |
| YTD return | -34.79% | -83.10% |
| 1-year return | -7.47% | -96.56% |
| 5-year return | -93.89% | — |
| EPS (TTM) | $-0.43 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.46 | $146.09 |
| 52-week low | $0.84 | $1.92 |
| Distance from 52-week high | -60.50% | -96.60% |
| Analyst consensus | none | — |
| Avg. price target upside | +710.00% | — |
| Average volume | 66.02K | 94.78K |
| Shares outstanding | 16.67M | — |
| Employees | 5 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed PBM by 89.1 percentage points over the past year.
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
MRKR vs PBM FAQ
Which stock has performed better over the past year, MRKR or PBM?
MRKR returned -7.47% over the past 12 months, compared with -96.56% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Marker Therapeutics and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.